| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 30th September 2020 | Vipin K Garg | 2,015 | Payment by withholding | $13.20 | $26,598.00 |
| 24th September 2020 | David Drutz | 16,850 | Exercise of derivative | $0.00 | |
| 24th September 2020 | Mitchel Sayare | 25,275 | Exercise of derivative | $0.00 | |
| 24th September 2020 | Wayne Pisano | 16,850 | Exercise of derivative | $0.00 | |
| 24th September 2020 | Philip Hodges | 16,850 | Exercise of derivative | $0.00 | |
| 24th September 2020 | John Gill | 16,850 | Exercise of derivative | $0.00 | |
| 24th September 2020 | Klaus Schafer | 16,850 | Exercise of derivative | $0.00 | |
| 30th August 2020 | Vipin K Garg | 2,015 | Payment by withholding | $17.62 | $35,504.30 |
| 18th August 2020 | Healthcare Capital Partners Iii, L.P. Venrock | 101,000 | Open or private purchase | $2.62 | $264,620.00 |
| 17th August 2020 | Healthcare Capital Partners Iii, L.P. Venrock | 250,000 | Open or private purchase | $2.57 | $642,500.00 |
Altimmune
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. Its portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system.
Ticker: ALT
Sector: Commercial Services
Industry: Miscellaneous Commercial Services
SEC Central Index Key (CIK): 1326190
Employees: 25
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
We weren't able to import Fundamental data from the SEC disclosure.
There were no Red Flags found
Fundamentals
We weren't able to import Fundamental data from the SEC disclosure.
News
Behind real estate’s surprise 2020 boom and what comes next
24th October 2020
US judge will not reverse decision on WeChat app store ban
23rd October 2020